KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Treasury Shares (2016 - 2024)

Historic Treasury Shares for Jazz Pharmaceuticals (JAZZ) over the last 13 years, with Q4 2024 value amounting to $4.0 million.

  • Jazz Pharmaceuticals' Treasury Shares rose 1319.11% to $4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.0 million, marking a year-over-year increase of 1319.11%. This contributed to the annual value of $4.0 million for FY2024, which is 1319.11% up from last year.
  • Jazz Pharmaceuticals' Treasury Shares amounted to $4.0 million in Q4 2024, which was up 1319.11% from $2.8 million recorded in Q3 2024.
  • In the past 5 years, Jazz Pharmaceuticals' Treasury Shares ranged from a high of $4.0 million in Q4 2024 and a low of $800000.0 during Q2 2023
  • In the last 5 years, Jazz Pharmaceuticals' Treasury Shares had a median value of $1.7 million in 2020 and averaged $2.1 million.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Treasury Shares crashed by 2000.0% in 2020 and then surged by 11538.46% in 2024.
  • Over the past 5 years, Jazz Pharmaceuticals' Treasury Shares (Quarter) stood at $1.9 million in 2020, then surged by 40.1% to $2.6 million in 2021, then rose by 21.97% to $3.2 million in 2022, then grew by 11.03% to $3.6 million in 2023, then rose by 13.19% to $4.0 million in 2024.
  • Its last three reported values are $4.0 million in Q4 2024, $2.8 million for Q3 2024, and $1.5 million during Q2 2024.